Document: NRC Regulatory Guide
Document ID: 96baa826-d3bb-478b-8f38-e74500f6d433
Document Type: regulatory_guide
Title: 06/2009 (Rev. 2)
Source: NRC Regulatory Guide Division 1
Source URL: https://www.nrc.gov/docs/ML0911/ML091170109.pdf
Revision Date: 2023-06
Chapter: 
Section ID: RG-1.21
CFR Part: 
CFR Title: 

Content:
e performed and maintained for purposes of demonstrating compliance with staff position C in Regulatory Guide 1.109. A thoroughly designed and documented evaluation of a less significant release point could also assist in the evaluation and characterization of abnormal releases and abnormal discharges. Real exposure pathways are identified for routine discharges and direct radiation based on the results of the land use census. Dose calculations should typically be performed based on real exposure pathways. Conversely, dose assessments (i.e., surveillances and dose calculations) are not needed for exposure pathways that do not exist at a site. For example, if the land use census does not identify the existence of an ingestion exposure pathway involving a milk animal, the licensee is not required to assess that route of exposure for the ingestion exposure pathway. Similarly, if a licensee discharges liquid radioactive waste to a body of water (either surface water or ground water) and that body of water is not used as a source of drinking water (either private or public), a drinking water assessment is not required. For purposes of reporting information in the ARERR, there is a distinction between dose assessments for Appendix I to 10 CFR Part 50 and hazard assessments that may be conducted for on-site spills and leaks as outlined in 10 CFR 20.1501 (where bounding estimates may be necessary). (See “bounding dose estimates” in Section 5.1.) 5.8 Dose Assessments for 10 CFR 20.1301(e) To show compliance with 10 CFR 20.1301(e), dose assessments should be reported according to the generally applicable environmental radiation standards promulgated by EPA at 40 CFR Part 190, with consideration of Regulatory Position 5.6 and in a format similar to that shown in Table A-5 of the appendix to this guide. 5.8.1 The following should be reported: 1. whole body dose to the maximum individual member of the public 2. thyroid dose to the maximum individual member of the public 3.